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PURPOSE. We conducted a systematic review and meta-analysis of observational studies to
evaluate the effect of oral statins on intraocular pressure (IOP) and the incidence and
progression of glaucoma.
METHODS. This was a systematic review of the literature and meta-analysis. Searches of
PubMed/Medline and Embase were conducted to include all types of studies. Gray literature
abstracts were also considered for inclusion. Last search date was February 2016. Risk of bias
was assessed using the Newcastle-Ottawa scale independently by two reviewers. Odds ratios
(OR) or hazard ratios (HR) and 95% confidence intervals (CI) were extracted from each study.
Pooled ORs for incidence of glaucoma were calculated using a random-effects model.
RESULTS. We identified seven cohort studies, three case–control studies, and one cross-
sectional study with a total number of 583,615 participants. No randomized controlled trials
were retrieved. Pooled ORs demonstrated a statistically significant association between short-
term statin use (2 years) and reduced incidence of glaucoma (OR 0.96, 95%CI 0.94, 0.99).
Pooled ORs of long-term statin use (>2 years) did not demonstrate statistically significant
reduction in incidence of glaucoma (OR 0.70, 95%CI 0.46, 1.06). There was inconsistent
evidence for the protective effect of statins against the progression of glaucoma, although
there was no standard definition for progression across studies. There was no significant
difference in IOP associated with statin use.
CONCLUSIONS. Short-term statin use is associated with a reduced incidence of glaucoma. The
effect of statins on glaucoma progression and IOP is uncertain.
Keywords: glaucoma, statins, incidence, progression, intraocular pressure
Glaucoma is a progressive optic neuropathy characterizedby structural optic nerve head changes and visual field
loss. The leading cause of irreversible blindness worldwide,
glaucoma affects 64.3 million people, and this is expected to
increase to 111.8 million by 2040.1 The global prevalence of
open-angle glaucoma (OAG) between 40 and 80 years is
estimated at 3.54% worldwide.1,2
Major risk factors for OAG include age and intraocular
pressure (IOP).3 Intraocular pressure is currently the only
modifiable major risk factor for OAG development and
progression.4 Medical and surgical therapies have been
successfully introduced that lower IOP by reducing aqueous
production and increasing outflow; however, these therapies
are not without adverse effects. Furthermore, it is not
uncommon for the disease to progress despite successful IOP
reduction.5 Therefore demand continues for the discovery of
novel therapeutic agents that offer patients protection from the
onset and progression of glaucomatous visual loss.
During development pipelines, 90% of drug candidates fail
at some point, leaving only 10% as a marketable product.6
Failure late in clinical development results in greater amounts
of time, money, and effort invested with little or no return.
Drug repurposing is a process of finding new uses for drugs
outside the scope of the original indication.7 This benefits from
reduced risk and costs because the drug candidates have either
already been approved for clinical use or been through several
stages of clinical development with known safety and
pharmacokinetic profiles.8
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase, which is a rate-limiting enzyme
necessary for the production of the intermediate product L-
mevalonate in the biosynthetic pathway of cholesterol.9 Statins
are a relatively well tolerated class of cholesterol-lowering
medication commonly prescribed in patients with dyslipidemia
for the primary and secondary prevention of cerebrovascular
and cardiovascular disease. Clinical and scientific evidence
suggests that statins are capable of reducing the risk of
cerebrovascular and cardiovascular disease independent of
their effect on cholesterol levels.10,11 The so-called pleiotropic
properties of statins such as inhibition of isoprenylation of Rho-
GTPase12 and immunomodulation13 have been proposed to
protect retinal ganglion cells (RGCs) against glaucomatous
damage.14 Thus there has been increasing interest in the
potential role of statins in glaucoma pathologic mechanisms
and therapeutics.15
The purpose of this literature review is to examine the
current clinical and epidemiologic evidence investigating the
strength and consistency of the association between clinical
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statin use and the incidence or progression of glaucoma and its
effects on IOP.
METHODS
We followed the MOOSE guidelines16 and registered our
review at PROSPERO International Prospective Register of
Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO,
registration no: CRD42015014875). This article adheres to
the PRISMA statement17 checklist for the preferred reporting
of systematic reviews and meta-analysis.
Eligibility Criteria for Considering Studies for This
Review
This systematic review focused on studies that investigated the
association between statin use and glaucoma incidence or
progression and the effect on IOP. Included studies were
limited to primary research; however, they were not limited by
design, sample size, participants, follow-up, or primary
outcome measures.
Search Methods for Identifying Studies
Medline (1946-February week 3 2016) and Embase (1980-2016
week 8) were searched on 24 February, 2016 (Fig. 1). The
search strategy used subject headings in both databases: MeSH
terms in Medline and Emtree terms in Embase (Appendix 1).
PubMed and Google Scholar searches were also conducted
using the search terms ‘‘glaucoma’’ and ‘‘statins’’ to pick up
any articles that had not been added to Medline yet. The search
strategies were limited to human studies and English language.
Included studies were limited to published studies to the
exclusion of editorials, commentaries, and article summaries.
FIGURE 1. Search strategy flow diagram.
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Reference lists of articles were also interrogated for additional
relevant papers. Abstracts were also included.
Study Selection
Two authors (REH and PM) screened all titles and abstracts
generated from the searches to find studies that contained
information on the topic of interest. Full articles were retrieved
for detailed assessment by two authors, and papers that did not
meet the inclusion criteria were excluded.
Data Collection
Each study was characterized by extracting methodological
details onto a predesigned form by two independent review-
ers.18 Relevant outcomes and results were extracted into
another form and were screened for comparability. When there
were inconsistencies between reviewers’ opinions, there were
further discussions until consensus was reached. In studies in
which more than one estimate of effect was presented,
agreement was reached about the most appropriate ‘‘adjusted’’
estimate to include. Attempts were made to contact authors by
e-mail when papers presented insufficient data.
Risk of Bias Assessment
Risk of bias in the nonrandomized observational studies was
assessed using Newcastle-Ottawa Quality Assessment Scale
(NOS) for cohort and case–control studies as outlined in The
Cochrane Handbook of Systematic Reviews.18 The NOS
includes a star system in which a study is judged on three
domains (Appendix 2); representativeness of study group
selection (four items), comparability of groups (two items),
and ascertainment of either the exposure or outcome in case–
control studies or cohort studies (three items). Studies score a
star for each item addressed with a score ranging from 0 to 9.
Those studies scoring greater than 7 were distinguished from
scores 7 as having a lower risk of bias. The cutoff of 7 was
used as it had been adopted by a previous review.19 Two
independent reviewers repeated this process, and inconsisten-
cies were discussed until consensus was reached. When
insufficient information was available to ascertain the NOS
score, attempts were made to contact authors for further
details.
Data Synthesis and Analysis
Statistical analysis and meta-analysis were performed using
RevMan 5.3 software (The Cochrane Collaboration, Copenha-
gen, Denmark). We combined the results of different study
designs in the meta-analysis because we used the ‘‘rare disease
assumption’’ that odds ratios (OR) and risk ratios can be
considered equivalent when the disease has a prevalence less
than 5%.20,21 The v2 test of between-study heterogeneity was
used to test the null hypothesis that the underlying treatment
effect of statins is identical in all studies. The test statistic, Q,
follows a v2 distribution with the degrees of freedom equal to
the number of studies minus 1. The I2 statistic measured the
degree of inconsistency in the observed treatment effect of
statins by measuring the percentage of total variation across
the studies that is due to heterogeneity rather than chance.
Forest plots were used to graphically represent the investiga-
tion of heterogeneity. Within the forest plots, estimates were
stratified into subgroups on the basis of length of exposure to
statins (2 and >2 years) because the primary studies made
these stratifications. Overall effect size was then determined
for each of the subgroups. A further meta-analysis was
performed on estimates that were not subgrouped by length
of exposure to statins. We used the most conservative of the
two effects models, random effects, to estimate the pooled
effect size. This takes into account extra variations when
assuming that the studies are estimating different underlying
treatment effects. Publication bias was checked for using
funnel plots. Sensitivity analysis was performed to examine the
impact of poor-quality studies upon the meta-analysis. For the
purposes of the description of the results, study outcomes
were classified into the three domains relevant to glaucoma:
incidence, progression, and IOP.
RESULTS
The initial searches identified 307 records after the removal of
duplicates (Fig. 1). Following screening of these 307 records,
293 were excluded due to being either irrelevant or non-
epidemiologic studies. Full texts of 14 potentially relevant
manuscripts were retrieved. Three were excluded due to being
editorials, commentaries, or summaries of other included
studies. The remaining 11 studies explored the association
between primary OAG and statin use and were included. Of
these 11 studies, 9 were full studies and 2 were abstracts. No
randomized controlled trials were retrieved. Four studies
investigated glaucoma incidence, one study investigated both
glaucoma incidence and progression, and five other studies
investigated glaucoma progression. The effect of statin therapy
on IOP was reported in three studies. The publication dates for
all the studies ranged between 2004 and 2015.
Descriptions of populations, sample sizes, and outcome
measures are outlined in Table 1 and the design for each study
is defined in Table 2. The definition of the glaucoma-related
outcome measure, the method of ascertainment of statin
exposure, and the estimated effects of statins on incidence,
progression, and IOP for each included study are presented in
Tables 3 to 5, respectively.
Risk of Bias Assessment
Using the NOS, six cohort studies were judged to score ‡8 and
the remaining two cohort studies were judged to score 7 in
quality (Table 6). The lowest-scoring cohort studies were from
the two gray literature abstracts with scores of 5 and 0 out of 9.
One case–control study was judged to score ‡8 on the NOS,
and the other two were judged to have scored 7 (Table 7).
Statin Use and Incidence of Glaucoma
The association between statin use and incidence of glaucoma
was examined in five studies: two nested case–control studies,
one case–control study, one retrospective cohort study, and
one prospective cohort study. The outcomes for each study
were stratified by the length of exposure to statins as per the
primary studies and were then outlined in forest plots (Figs. 2,
3). A further meta-analysis was performed on outcomes
reported from studies that did not stratify by the length of
exposure (Fig. 4). Overall estimates for incidence of glaucoma
were presented in forest plots. For exposure to statins for 2
years, overall estimated OR was 0.96 (95%CI [confidence
interval] 0.94, 0.99) and for >2 years, overall estimate OR was
0.70 (95%CI 0.46, 1.06). Meta-analysis of outcomes that were
not stratified by length of exposure did not show a statistically
significant reduction in the incidence of OAG (OR 0.94, 95%CI
0.83, 1.06).
Among studies evaluating the short-term use of statins,
McGwin et al.,22 Owen et al.,23 and Stein et al.24 used
diagnostic read codes to define glaucoma incidence, whereas
Marcus et al.25 used a clinical diagnosis. McGwin et al.22 were
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TABLE 1. List of Features of All Included Studies
Author Design Dataset (Country) Population
McGwin et
al.,22 2004
Nested case–control
study
Veterans Affairs Medical Center (US) All male patients, 50 y or older, who had
at least 1 visit to BVAMC hospital
between January 1, 1997 and
December 31, 2001
De et al.
2006,
abstract
Retrospective cohort
study
University of California, San Francisco
(UCSF), and the San Francisco Veterans
Affairs Medical Center (US)
retrospective chart review
Patients with OAG
De Castro et
al.,27 2007
Retrospective cohort
study
OAG suspects at the Beckman Vision
Center (BVC), UCSF (US)
Glaucoma suspects at BVC UCSF from
January 2001 to June 2006
Tong,28 2008,
abstract
Retrospective cohort
study
n.r. n.r.
Iskedjian et
al.,29 2009
Retrospective cohort
study
RAMQ database repository of
prescription claims (Canada)
Random sample from 75% of 2.7 million
plan recipients
Leung et
al.,30 2010
Prospective cohort
study
Hong Kong Eye Hospital (Hong Kong) Prospectively recruited cohort of patients
from Hong Kong Eye Hospital
Owen et
al.,23 2010
Nested case–control
study
177 practices in DIN-LINK UK primary
care database (UK)
Patients in DIN-LINK database of primary
care records with minimum of 5-y
continuous high-quality records
Marcus et
al.,25 2012
Prospective cohort
study
Rotterdam Study (The Netherlands) Participants of the Rotterdam Study n ¼
7983
Stein et al.,24
2012
Retrospective cohort
study
i3 InVision Data Mart database;
beneficiaries in a managed care
network throughout the United States
(US)
Beneficiaries who received any form of
eye care from 2001 to 2009 n ¼
10,326,832
Khawaja et
al.,31 2014
Cross-sectional
study, within
cohort study
EPIC-Norfolk eye study (UK) EPIC study participants n ¼ 8623
Chen et al.,26
2015
Case–control study National Health Insurance program
(Taiwan)
Longitudinal Health Insurance Database
(LHID)
A, atorvastatin; A/ab, atorvastatin and amlodipine besylate; C, cerivastatin; F, fluvastatin; FU, follow-up; GAT, Goldmann applanation tonometry;
L, lovastatin; Ln, niacin and lovastatin; n.r., not reported; ORA, ocular response analyzer; POAG, primary open-angle glaucoma; PGA, prostaglandin
analogue; P, pravastatin; P/ba, pravastatin and buffered aspirin; R, rosuvastatin; S, simvastatin. BVAMC, Birmingham Veterans Affairs Medical Center;
EPIC, European Prospective Investigation into Cancer; HFA, Humphreys Field Analyser; NTG, Normal Tension Glaucoma; RAMQ, Regie de
l’assurance malaide du Quebec; Se, Simvastatin and ezetimibe.
1, age; 2, sex; 3, diabetes; 4, lipid metabolism disorders; 5, hypertension; 6, cardiovascular disease (ischemic heart disease); 7, cerebrovascular
disease; 8, arterial disease; 9, disc hemorrhages; 10, asthma; 11, chronic obstructive pulmonary disease; 12, IOP; 13, myopia; 14, family history of
glaucoma; 15, NSCLD use; 16, concomitant medications; 17, race; 18, obesity; 19, hypotension; 20, sleep apnea; 21, migraine; 22, ocular
comorbidities; 23, education level; 24, body mass index; 25, central corneal thickness; 26, cancer; 27, hypothyroidism; 28, autoimmune disease; 29,
vasculitis; 30, depression; 31, Charlson comorbidity index; 32, frequency of eye care visits.
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unable to demonstrate a statistically significant effect of statin
use for less than 12 months (OR 1.03, 95%CI 0.77, 1.39) or for
12 to 23 months (OR 0.75, 95%CI 0.46, 1.23). Consistent with
this result, Owen et al.23 did not find a significant association
between short-term statin use and glaucoma incidence when
adjusted for a socioeconomic index, comorbidities, and other
medications taken (OR 0.98, 95%CI 0.89, 1.08). Marcus et al.25
were unable to demonstrate a statistically significant protective
effect of cumulative statin use for less than 2 years (hazard ratio
[HR] 0.89, 95%CI 0.41, 1.94). However, Stein et al.24 found
statistically significant protective effects of statin use for 1 year
using two parameters of glaucoma incidence: OAG onset from
no previous diagnosis (HR 0.960, 95%CI 0.933, 0.988) and
incidence of medical treatment for OAG (HR 0.950, 95%CI
0.924, 0.976).
Regarding the long-term use of statins, three studies
reported an association with reduced OAG incidence. McGwin
et al.22 and Stein et al.24 used diagnostic read codes to define
TABLE 1. Extended
Author Sample Size Age Females Study Duration, Follow-Up Statin Types
McGwin et
al.,22 2004
667 cases and 6667 controls ‡50 y 0% January 1, 1997 to December
31, 2001
A, C, F, P, S, L
De et al.
2006,
abstract
315 patients; numbers in exposed
and control groups not reported
n.r. n.r. n.r. n.r.
De Castro et
al.,27 2007
76 patients, 149 eyes 11–85 y 64.5% January 2001 to June 2006
Statin-only group mean FU
26.8 6 10.7 mo
Statin and aspirin group
mean FU 30.8 6 14.2 mo
Control group mean FU
28.3 6 11.5 mo
n.r.
Tong,28 2008,
abstract
353 patients with normal-tension
glaucoma; numbers in exposed
and control groups not reported
n.r. n.r. n.r. n.r.
Iskedjian et
al.,29 2009
8548 patients <20–‡80 y
Mean age 70.5
59% January 1, 2001 to March 1,
2005
n.r.
Leung et
al.,30 2010
256 patients with NTG, 256 eyes
following 1 exclusion
18 y or older 35.5% of those
taking statins
46.2% of those
not taking statins
36 mo S
Owen et
al.,23 2010
17,556 individuals; 8778 cases and
8778 controls
40–90 y
Mean age 70
53% 5 y S, P, F, A, C, R
Marcus et
al.,25 2012
3939 participants who did not
have OAG at baseline
‡55 y 49.1% incident
POAG
58% no incident
POAG
56.6% of
cholesterol-
lowering drug
users
58.9% nonusers of
cholesterol-
lowering drugs
Mean follow-up 9.8 y
Incident POAG: follow-up
ended at first visit with
glaucomatous visual field
loss
Without incident POAG:
follow-up was from
baseline to last visit with
reliable perimetry
S, P, F, A, C, R
Stein et al.,24
2012
524,109 persons with ‡1
diagnosis of hyperlipidemia
60 y or older 56.5% of
beneficiaries who
did not develop
OAG
56.0% of
beneficiaries who
developed OAG
January 1, 2001 to December
31, 2009
L, Ln C, A A/
ab, R, F, P,
P/ba, S, Se
Khawaja et
al.,31 2014
7093 participants following
exclusion criteria
48–92 y
Mean age 68 y
56% 2004–2011 n.r.
Chen et al.,26
2015
1276 cases, 12,760 controls Mean age 64.1 y 49.5% 2004–2011 S, L, P, F, A, R
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OAG incidence, whereas Marcus et al.25 used a clinical
diagnosis. McGwin et al.22 demonstrated a statistically signif-
icant association between incidence of glaucoma and statin use
for greater than 23 months (OR 0.60, 95%CI 0.39, 0.92). In
support of this, Marcus et al.25 demonstrated a statistically
significant protective effect of cumulative statin use for more
than 2 years (HR 0.46, 95%CI 0.23, 0.94). Finally, Stein et al.24
found statistically significant protective effects of statin use for
2 years using OAG onset from no previous diagnosis (HR 0.922,
95%CI 0.870, 0.976) and incidence of medical treatment for
OAG (HR 0.902, 95%CI 0.854, 0.953).
Our meta-analysis suggests that statin therapy for 2 years
confers a 4% reduction in the incidence of OAG (Fig. 2) while
statin therapy for >2 years did not confer a statistically
significant reduction in the incidence of OAG (Fig. 3). Statin
use not stratified by length of exposure to statins also did not
confer a statistically significant reduction in the incidence of
OAG (Fig. 4).
TABLE 1. Extended
Author
Confounders
Adjusted For Outcomes Measured
McGwin et
al.,22 2004
1, 3, 4, 5, 6, 7, 8 1) Statin use, yes/no: OR of glaucoma incidence associated with statin use
2) Statin use, current/past: OR of glaucoma incidence associated with current or past statin
use
3) Statin use, <12 mo, 12–23 mo, >23 mo: OR of glaucoma incidence associated with statin
use, stratified by length of treatment
De et al.
2006,
abstract
n.r. 1) Mean deviation: mean change per year
2) Pattern standard deviation: mean change per year
De Castro et
al.,27 2007
1, 2, 17, 12, 25,
13, 5, 3, 21,
26, 4, 27, 28,
7, 8, 29
1) Visual field progression: glaucoma hemifield test (HFA)
2) Mean change in optic nerve parameters: confocal laser ophthalmoscopy (CLSO): Heidelberg
Retinal Tomograph II
Tong,28 2008,
abstract
1, 12, 25, all not
adjusted for
1) Association of statins with stable disease: univariate analysis
Iskedjian et
al.,29 2009
1, 2 1) Proportion of glaucoma patients requiring adjunctive glaucoma therapy within 12 mo of
starting PGA therapy dependent upon systemic medication (statin) use
Leung et
al.,30 2010
1, 7, 9 1) Visual field progression with HFA perimetry
2) IOP: GAT
Owen et
al.,23 2010
1, 2, 3, 6 1) Any statin prescription in 5 y before glaucoma diagnosis date, % of cases with statin
prescription versus % of controls with statin prescription
2) OR of statin treatment in cases (glaucoma) compared with controls
Marcus et
al.,25 2012
1, 2, 12, 13, 14,
15
1) HR of glaucoma incidence in statin exposure
a) Cumulative use for less than 2 y
b) Cumulative use for more than 2 y
2) IOP at follow-up (GAT) associated with statin use, adjusted for IOP-lowering treatment at
follow-up
Stein et al.,24
2012
1, 2, 3, 5, 15, 16,
17, 18, 19, 20,
21, 22, 23
1) Incidence of OAG from no previous diagnosis
2) Progression from glaucoma suspect to OAG
3) Need for medical intervention for OAG
4) Need for surgical intervention for OAG
Khawaja et
al.,31 2014
1, 2, 24 1) IOP (ORA): mean Goldmann correlated IOP and association with statin use
Chen et al.,26
2015
3, 5, 15, 30, 31,
32
1) Statin exposure, yes/no: OR of glaucoma incidence associated with statin exposure
2) Statin exposure: none, <30, 30–119, ‡120 defined daily doses per year
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Publication Bias
Funnel plots that plot the OR on the log scale (x-axis) against the
standard error of the log odds (y-axis) were used to examine
publication bias and the possibility of type 1 error. In Figure 5
there is no evidence of asymmetry in the funnel plot examining
short-term statin use, and consequently no publication bias is
apparent in these studies. Funnel plots were not conducted for
longer-term statin use and statin use not stratified by length of
exposure because too few studies were available.
Sensitivity Analysis
In the sensitivity analysis, the overall heterogeneity and
effect size was calculated following exclusion of the studies
TABLE 5. Features and Results of Studies Investigating Association Between Statin Use and IOP
Author
Glaucoma Parameter
Definition, IOP
Method Used to Quantify
Statin Use Statin Use Definition
Summary of Statin-
Related Primary
Outcomes
Leung et al.,30
2010
Glaucoma progression
IOP: GAT
Systemic use of
medications including
statins, simvastatin only,
noted from
computerized database
Statin use positive and
statin use negative;
continual statin use was
checked at each follow-
up visit and verified by
physician prescription
and patient purchase
There were no statistically
significant differences
between:
Median untreated IOP
measurement in the
group (n ¼ 31) that
received statins, 15.04 6
2.47 mm Hg, compared
to the group (n ¼ 225)
who did not, 14.37 6
2.78 mm Hg P ¼ 0.213
Maximum untreated IOP
measurements in the
group (n ¼ 31) that
received statins, 17.61 6
2.93 mm Hg, compared
to the group (n ¼ 225)
who did not, 17.71 6
3.71 mm Hg P ¼ 0.865
Marcus et al.,25
2012
Glaucoma incidence
IOP: GAT
Automated pharmacy
records; provided
information on
medication name, date of
first prescription, and
duration of use
No use
Cumulative use for less
than 2 y
Cumulative use for more
than 2 y
Median length of statin
use among statin users
was 1424 d
Multiple regression analysis
of IOP association with
statin use; b 0.006,
95%CI 0.262, 0.249 P
¼ 0.96
Khawaja et al.,31
2014
Cross-sectional prevalence
IOP: ocular response
analyzer
Participants brought all
current medication and
associated
documentation to
ophthalmic examination
where they were
recorded on electronic
case record form
Cross-sectional prevalence
of statin use
1565 of 7093 patients in
the study taking statins
Mean IOP of participants
taking statins versus
participants not taking
statins, adjusted for
possible confounders
(age, sex, body mass
index, and HbA1c),
15.67 vs. 15.99 mm Hg
Difference 0.31, 95%CI
0.51, 0.12 P ¼ 0.002
Linear regression model
of IOP association with
statin use; b 0.29,
95%CI 0.50, 0.09 P ¼
0.003
Following adjustment for
nitrate use; b 0.21,
95%CI 0.42, 0.00 P ¼
0.045
Following adjustment for
beta-blocker use;
b 0.11, 95%CI 0.31,
0.10 P ¼ 0.31
GAT, Goldmann Applanation Tonometry; HbA1c, Glycosylated Haemoglobin.
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scoring 7 in the NOS (n ¼ 2). When McGwin et al.22 was
removed from the analysis there was no change in the
pooled OR comparing statin use for 2 years versus
controls (OR 0.96, 95%CI 0.94, 0.99). There was a change
in the pooled OR comparing statin use for >2 years versus
controls when McGwin et al.22 was removed but it did not
affect the statistical significance of the result (OR 0.71,
95%CI 0.37, 1.38). When McGwin et al.22 and Chen et al.26
were removed from the analysis of pooled ORs that were
not stratified by length of exposure, there was no effect on
the statistical significance of the result (OR 0.77, 95%CI
0.44, 1.35).
Statin Use and Progression of Glaucoma
The association between statin use and progression of
glaucoma was reported in four full studies and two abstracts
(Table 4). Among these there were five retrospective cohort
studies and one prospective cohort study. There were different
definitions of glaucoma progression across all of the studies,
which meant that meta-analysis could not be performed. There
were conflicting results across studies regarding association
between statin use and progression. De and coauthors (De M,
et al. IOVS 2006;47:ARVO E-Abstract 3398) defined progres-
sion as the average change in mean deviation of the visual field
test per year. They found no statistically significant difference
in the average change in mean deviation per year or pattern
standard deviation per year between controls and users of
statin for greater than 23 months. De Castro et al.27 defined
OAG progression using various clinical parameters. They
found no statistical difference among the number of patients
who progressed to ‘‘outside normal limits’’ on glaucoma
hemifield visual field test in the statin group compared to
controls. However, they did find significant differences in the
progression of multiple confocal scanning laser ophthalmos-
copy parameters per year including rim volume, retinal nerve
fiber layer cross-sectional area, and mean global retinal nerve
fiber layer thickness, which favored the statins group when
adjusted for multiple systemic and ocular factors. An abstract
by Tong28 in 2008 found that univariate analysis of statin use
was correlated with stable disease. However, descriptions of
the study population, method of assessment, and adjustment
for confounders were not reported. The study scored 0 on
NOS. Iskedjian et al.29 used read code data for the addition of
adjunctive medical therapy in those taking prostaglandin
analogues for glaucoma as a surrogate marker for progression.
They found that the proportion of patients initiating adjunc-
tive medical therapy for glaucoma in the statin group was less
than in those not taking any systemic medication, although
this did not reach statistical significance. In a prospective
cohort study of normal-tension glaucoma, Leung et al.30 found
that the proportion of patients who took statins in the group
that remained stable was significantly higher than the
proportion of patients who took statins in the group who
progressed. A logistic regression model adjusting for a history
of disc hemorrhages, cerebrovascular disease, and age at
baseline showed that simvastatin use conferred a significant
protective effect against visual field progression. In a
retrospective cohort study, Stein et al.24 used read code
changes from ‘‘suspect OAG to OAG diagnosis’’ and ‘‘surgical
treatment for OAG’’ as proxies for progression. Those who
took statins for 1 or 2 years had decreased hazard of
progressing to OAG from OAG suspect compared to those
who did not receive statins (Table 4). However, hazard of an
individual with OAG later requiring laser or incisional
glaucoma surgery was not significantly reduced with statin
exposure.T
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Statin Use and IOP
The association between statin use and IOP was presented in
three studies (Table 5). Leung et al.30 and Marcus et al.25
reported no significant changes in IOP associated with statin
use. Khawaja et al.31 reported a significant reduction in IOP
among statin users compared to non-statin users when
adjusted for age and sex (b 0.31, 95%CI 0.51, 0.12 P ¼
0.002). However, when adjusted for beta-blocker therapy, the
association was no longer significant.
DISCUSSION
To date this is the only systematic review that evaluates the
association between statin use and glaucoma. Our search
yielded no randomized controlled trials but 11 observational
and case–control studies with sample sizes ranging from 76 to
over 500,000 participants. Meta-analysis of the effect of short-
term statin therapy on the incidence of glaucoma demonstrat-
ed a 4% reduced risk of glaucoma; however, long-term therapy
did not demonstrate a statistically significant effect. Similarly,
we did not find any significant association between statin use
and incidence of glaucoma when outcomes were not stratified
according to length of exposure to statin therapy. A previous
meta-analysis by Macedo et al.19 evaluating the unintended
effects of statins identified only three studies investigating the
association with glaucoma and statin use, whereas we have
identified a more complete set of evidence. Furthermore those
authors did not report on short- versus long-term exposure to
statin therapy. Macedo et al.19 found an overall pooled OR
estimate of 0.86 (95%CI 0.69, 1.08).
Read codes are a system by which diagnostic codes are
allocated to patients within databases based on the clinical
diagnosis as entered in the system, but not necessarily
independently validated. The use of read code to classify
glaucoma incidence and progression in several stud-
ies22–24,26,29 poses the risk of misclassification bias. Caution
must therefore be employed when interpreting these studies.
By far the largest identified study was conducted by Stein et
al.24 with a study population of over 500,000 individuals. The
sample was identified by the individuals’ hyperlipidemia status.
Hence the generalizability of these results may be limited to the
TABLE 7. Newcastle-Ottawa Scale: Case–Control Studies
McGwin et al.,22 2004 Owen et al.,30 2010 Chen et al.,26 2015
Selection
Is the case definition adequate? Yes, e.g., record linkage or based
on self-reports
Yes, e.g., record linkage or based
on self-reports
Yes, e.g., record linkage or based
on self-reports
Representativeness of the cases Potential for selection bias or not
stated
*Consecutive or obviously
representative series of cases
Potential for selection bias or not
stated
Selection of controls Hospital controls *Community controls *Community controls
Definition of controls *No history of disease, endpoint *No history of disease, endpoint *No history of disease, endpoint
Comparability
Comparability of cases and
controls on the basis of design
or analysis, most important
factor study controls for
*Age *Year of birth *Age
Study controls for any additional
factor
*Diabetes, lipid metabolism
disorders, hypertension,
cardiovascular disease,
cerebrovascular disease, arterial
disease
*Practice, sex, ACORN index,
selected comorbidities before
case diagnosis, number of drugs
types prescribed
*Sex, diabetes, year of
hyperlipidemia diagnosis,
hypertension, depression,
Charlson comorbidity index,
NSCLD use
Exposure
Ascertainment of exposure *Secure record *Secure record *Secure record
Same method of ascertainment
for cases and controls
*Yes *Yes *Yes
Nonresponse rate *Same rate for both groups *Same rate for both groups *Same rate for both groups
Total stars 6 8 7
ACORN, a classification of residential neighborhoods.
* A star awarded to the study for that component of the Newcastle Ottawa Scale.
FIGURE 2. Forest plot of incidence of glaucoma and statin use 2 years versus controls. McGwin et al.,22 refers to exposure for <12 months (top)
and 12 to 23 months (second from top). McGwin et al.,22 (second from top): Upper limit of 95%CI (1.38) is not exactly equivalent to upper limit of
95%CI in Table 3 (1.39) due to rounding in meta-analysis software.
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population with hyperlipidemia. As the largest study identified,
the study by Stein et al.24 carries most weight; however, it is
retrospective and uses read code data to define glaucoma, and
therefore the quality of evidence from this study is relatively
poor and the results need to be interpreted with caution.
The use of nonstatin cholesterol-lowering drugs (NSCLDs),
a possible confounding factor, was reported by McGwin et
al.,22 Stein et al.,24 Marcus et al.,25 and Chen et al.26 McGwin et
al.22 found that NSCLD use for less than 12 months was
associated with reduced incidence of OAG (OR 0.38, 95%CI
0.18, 0.79), and Stein et al.24 found that persons who took
NSCLD for 2 years had a 14% decreased risk of being
prescribed a glaucoma medication (adjusted HR 0.862, 95%CI
0.785, 0.946). In contrast, Marcus et al.25 and Chen et al.26 did
not demonstrate statistically significant protective effects of
NSCLDs in glaucoma. In these studies NSCLDs were defined as
a heterogeneous group of medications encompassing various
classes of drugs. Certain classes of NSCLDs such as peroxisome
proliferator–activated receptor alpha (PPARa) agonists (fi-
brates) have been shown to exhibit immunomodulatory
pleiotropic effects independent of their lipid-lowering proper-
ties32 and have been shown to work synergistically with
statins.33–35 Statins may induce IOP lowering by increasing
aqueous outflow.36 The confounding effect of systemic beta-
blocker therapy on the effect of statins on IOP lowering was
reported by Khawaja et al.31 They reported that the observed
IOP-lowering effect of statins was no longer significant
following adjustment for systemic beta-blocker therapy. Thus
FIGURE 3. Forest plot of incidence of glaucoma and statin use >2 years versus control. Marcus et al.,25 upper limit of 95%CI (0.92) is not exactly
equivalent to upper limit of 95%CI in Table 3 (0.94) due to rounding in meta-analysis software.
FIGURE 4. Forest plot of incidence of glaucoma and statin use from outcomes not stratified by length of exposure. Marcus et al.,25 upper limit of
95%CI (0.94) is not exactly equivalent to upper limit of 95%CI in Table 3 (0.96) due to rounding in meta-analysis software. Owen et al.,30 upper limit
of 95%CI (1.07) is not exactly equivalent to upper limit of 95%CI in Table 3 (1.06) due to rounding in meta-analysis software.
FIGURE 5. Funnel plot examining publication bias investigating short-term (2 years) statin use and incidence of glaucoma.
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the confounding effects of NSCLDs and systemic beta-blockers
should be considered in the design and analysis of future
interventional studies.
From our study we cannot rule out confounding by
indication,37 and we must ask if it is the hyperlipidemia that
might be protective or the statin use. A study by Newman-
Casey et al.38 showed that hyperlipidemia was associated with
a decreased risk in developing OAG; however, they could not
determine whether it was the treatment for hyperlipidemia
that reduced the risk or the hyperlipidemia itself. A study by
Wang et al.39 showed that dyslipidemia was not significantly
associated with the prevalence of glaucoma; however, they
showed that dyslipidemia was associated with higher IOP and
beta zone of parapapillary atrophy in a Chinese population.
Chen et al.26 demonstrated that higher dosages of statins are
associated with increased risk of OAG (OR 1.24, 95%CI 1.03,
1.49). They proposed that higher dosages of statins were an
indication of poorer lipid control that was the cause of the
increased risk of OAG.
There were a number of strengths in this review. The
sensitivity of our search strategy was maximized by restricting
the exclusion criteria during the screening stage. However, the
observational studies included are susceptible to various
systematic biases depending on whether they are case–control
or cohort designs. Case–control studies are generally prone to
selection bias and require strict case definition to prevent
misclassification bias. Cohort studies are considered method-
ologically superior to case–control studies; however, they are
expensive and must be well conducted to prevent loss to
follow-up. Cross-sectional studies are useful to estimate
prevalence but are of limited value when investigating
incidence. For each study we addressed the risk of bias using
a range of tools recommended in The Cochrane Handbook of
Systematic Reviews.18 In addition, the comprehensive ap-
proach adopted to ascertain confounding factors in each study
added to the strength of the review. Potential confounding
factors identified and controlled for in each study are outlined
in Table 1.
Weaknesses of the study include the exclusion of literature
in languages other than English. To reach a wider audience,
significant results tend to be published in English; therefore a
degree of publication bias may be introduced by language
restriction. Our investigation of publication bias did not reveal
type 1 error in the results of studies investigating the short-
term effects of statin use and incidence of glaucoma. A
limitation in our study is that we had too few studies to
investigate possible publication bias in studies investigating
long-term statin exposure and those not stratified by length of
exposure to statins. Although abstracts were identified and
included, a formal search of gray literature databases was not
performed, which may have contributed to publication bias.
Another limitation in the reporting of our results is defining
glaucoma as ‘‘commencing glaucoma medications’’ because
some people may have ocular hypertension and not glaucoma.
However, we addressed this by not including these estimates in
the meta-analysis.
In conclusion, the results of our meta-analysis provide
evidence for the association between the short-term use of
statin therapy and a reduced incidence of glaucoma. However,
the observational design of the studies in the meta-analysis
limits the ability to make inferences about whether or not
exposure to statins causes reduced incidence of glaucoma.
There was inconsistent evidence for the IOP-lowering effect of
statins and the effect of statins on the progression of OAG. The
associations observed in this review warrant a prospective
interventional randomized controlled study with short- and
long-term follow-up to provide further insight into the role of
statin therapy in the prevention of onset or progression of
glaucoma and its effects on IOP.
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APPENDIX 1
TABLE A1. Search Strategies
Search Results
Medline 24FEB2016
1. exp hydroxymethylglutaryl-CoA reductase inhibitors/or exp simvastatin/or exp lovastatin/ 31,637
2. exp glaucoma, open-angle/or exp glaucoma/or exp low-tension glaucoma/ 45,003
3. 1 and 2 15
4. exp intraocular pressure/ 31,292
5. 1 and 4 15
6. 3 or 5 23
7. limit 6 to (english language and humans) 23
Embase 24FEB2016
1. exp hydroxymethylglutaryl coenzyme A reductase inhibitor/ 108,897
2. exp glaucoma/or exp low-tension glaucoma/or exp open angle glaucoma/or exp primary glaucoma/ 69,034
3. 1 and 2 287
4. exp intraocular pressure/ 41,038
5. 1 and 4 68
6. 3 or 5 319
7. limit 6 to (human and english language) 284
PubMed 24FEB2016
1. ‘‘statins AND
2. ‘‘glaucoma’’
Results¼ 30
Advanced Google Scholar 24FEB2016
1. ‘‘statins’’ AND
2. ‘‘glaucoma’’
Results¼ 6
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APPENDIX 2
NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALES
Case–Control Studies
Note: A study can be awarded a maximum of one star (*) for
each numbered item within the Selection and Exposure
categories. A maximum of two stars can be given for
Comparability.
Selection
(1) Is the case definition adequate?
(a) Yes, with independent validation*
(b) Yes, for example, record linkage or based on self-
reports
(c) No description
(2) Representativeness of the cases
(a) Consecutive or obviously representative series of
cases*
(b) Potential for selection biases or not stated
(3) Selection of controls
(a) Community controls*
(b) Hospital controls
(c) No description
(4) Definition of controls
(a) No history of disease (endpoint)*
(b) No description of source
Comparability
(1) Comparability of cases and controls on the basis of the
design or analysis
(a) Study controls for _______________ (select the
most important factor)*
(b) Study controls for any additional factor* (this
criterion could be modified to indicate specific
control for a second important factor)
Exposure
(1) Ascertainment of exposure
(a) Secure record (e.g., surgical records)*
(b) Structured interview where blind to case/control
status*
(c) Interview not blinded to case/control status
(d) Written self-report or medical record only
(e) No description
(2) Same method of ascertainment for cases and controls
(a) Yes*
(b) No
(3) Nonresponse rate
(a) Same rate for both groups*
(b) Nonrespondents described
(c) Rate different and no designation
Cohort Studies
Note: A study can be awarded a maximum of one star for each
numbered item within the Selection and Outcome categories.
A maximum of two stars can be given for Comparability.
Selection
(1) Representativeness of the exposed cohort
(a) Tr u l y r e p r e s e n t a t i v e o f t h e a v e r a g e
_______________ (describe) in the community*
(b) Somewhat representative of the average
______________ in the community*
(c) Selected group of users, for example, nurses,
volunteers
(d) No description of the derivation of the cohort
(2) Selection of the nonexposed cohort
(a) Drawn from the same community as the exposed
cohort*
(b) Drawn from a different source
(c) No description of the derivation of the nonex-
posed cohort
(3) Ascertainment of exposure
(a) Secure record (e.g., surgical records)*
(b) Structured interview*
(c) Written self-report
(d) No description
(4) Demonstration that outcome of interest was not
present at start of study
(a) Yes*
(b) No
Comparability
(1) Comparability of cohorts on the basis of the design or
analysis
(a) Study controls for _____________ (select the most
important factor)*
(b) Study controls for any additional factor* (this
criterion could be modified to indicate specific
control for a second important factor)
Outcome
(1) Assessment of outcome
(a) Independent blind assessment*
(b) Record linkage*
(c) Self-report
(d) No description
(2) Was follow-up long enough for outcomes to occur?
(a) Yes (select an adequate follow-up period for
outcome of interest)*
(b) No
(3) Adequacy of follow-up of cohorts
(a) Complete follow-up—all subjects accounted for*
(b) Subjects lost to follow-up unlikely to introduce
bias—small number lost: 20%, or description
provided of those lost)*
(c) Follow-up rate <80% and no description of those
lost
(d) No statement
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